The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery
Open accessAbstract
Abstract Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the delivery of small interfering RNA (siRNA). Free siRNA molecules suffer from unfavorable physicochemical characteristics and rapid clearance mechanisms, hampering the ability to reach the cytoplasm of target cells when administered intravenously. As a result, the therapeutic use of siRNA is crucially dependent on delivery strategies. LNPs can encapsulate siRNA to protect it from degradative endonucleases in the circulation, prevent kidney clearance, and provide a vehicle to deliver siRNA in the cell and induce its subsequent release into the cytoplasm. Here, the structure and composition of LNP–siRNA are described including how these affect their pharmacokinetic parameters and gene‐silencing activity. In addition, the evolution of LNP–siRNA production methods is discussed, as the development of rapid‐mixing platforms for the reproducible and scalable manufacturing has facilitated entry of LNP–siRNA into the clinic over the last decade. Finally, the potential of LNPs in delivering other nucleic acids, such as messenger RNA and CRISPR/Cas9 components, is highlighted alongside how a design‐of‐experiment approach may be used to improve the efficacy of LNP formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The latter contains positively charged ionizable amine groups (at low pH) to interact with the anionic mRNA during particle formation and also facilitate membrane fusion during internalization (Evers et al., 2018, Reichmuth et al., 2016).”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Evers et al., 2018
In the citing paper
“Together with the mRNA, these components form particles of about 60–100 nm in size by using a rapid mixing production technique (Evers et al., 2018).”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Evers et al., 2018
In the citing paper
“Note that the physicochemical and structural characteristics of mRNA LNPs will depend on the lipid composition, the ratio of mRNA to the total amount of (cationic) lipids, and the LNP synthesis (for a detailed review on these parameters also see [107]).”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Chaotic Mixer for Microchannels
Stroock, A. D., Dertinger, S. K. W., Ajdari, A., Mezić, I., Stone, H. A., & Whitesides, G. M. (2002) · Science · doi:10.1126/science.1066238 · Cited by 3,435
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Flagged first, then by citations
Research works printed but not linked: 5
- Leung A. K. K., 2015, Ph.D. Thesis
- Mozafari M. R., 2010, Liposomes, Method in Molecular Biology (Methods and Protocols)
- Walsh C., 2014, Drug Delivery Systems, 109
- Hope M., 1993, Liposome Technology, 123
- MacLachlan I., 1999, Curr. Opin. Mol. Ther., 1, 252
Cited by
Sorted by citations
Items 301–330 of 330
Roberto, G. T. E. C., Masiero, J. F., Stephano, M. A., & Bou‐Chacra, N. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108267
Amphiphilic dendrimers for nucleic acid delivery
Chen, J. (2021) · theses.fr (ABES) · doi:10.70675/9c958469z36faz4c64zb727z584addf9de34
Abuhassan, Q., Saleh, K. A., Jyothi, S. R., Samantsinghar, P., Prakash, P., Mukherjee, G., Sinha, A., & Boyqulov, T. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01469-3
Drug delivery nanosystems for skeletal muscle treatment in myotonic dystrophy
Repellin, M. (2022) · theses.fr (ABES) · doi:10.70675/905c40e8z03bdz417fz889dzf4930211a75b
Multifunctional nanocomposites for precise control over drug delivery
Andretto, V. (2022) · theses.fr (ABES) · doi:10.70675/7a7f57fez25f2z41a0z9072z3f3cc2aef2d6
Hengelbrock, A., Knierim, L., Schmidt, A., & Strube, J. (2026) · Processes · doi:10.3390/pr14091351
Chen, X., Jiang, L., Yang, H., Lu, J., Zhang, S., Dong, J., Li, H., Ye, Q., Jie, Z., Huimin, F., et al. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103406
Rancz, A., Schlagnitweit, J., Akrial, S.-E., Gajan, D., Gayet, L., Duong, N. T., Richert, L., Chami, M., Lollo, G., Peral, F., et al. (2026) · Small Methods · doi:10.1002/smtd.70797
“LNPs currently used in vaccines contain different types of lipids (an ionizable lipid, a PEGylated lipid, and helper lipids such as phospholipid and cholesterol), that spontaneously self-assemble into particles [ 6 ].”
Boutros, J., Wright, L., Oerlemans, S. K., Baali, H., & Falconer, R. J. (2026) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-026-15691-1
Hou, X., Gao, X., Wang, S., Wang, S., Cui, W., Ng, J. Y. A., Wang, S., Wang, B., Shen, Y., Yang, Q., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115159
Hosseinpour-Moghadam, R., Sadrai, S., & Toliyat, T. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2026.2686958
“On the manufacturing side, LNPs are well suited for continuous-flow microfluidic production, which enables precise control over particle size and cargo encapsulation ratio (Evers et al. 2018; Shepherd et al. 2021).”
Ionizable Silyl Lipids with Distinct Membrane Fluidity and mRNA Delivery Profiles
Patterson, L. A., Tran, W. N., Humeniuk, Y., Coppage, D. A., Agwaramgbo, E., Downey, O., O’Geen, H., Segal, D. J., & Franz, A. K. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00306
Liu, Z., Stewart, W., Teng, Y., Song, Y., Tang, M., Guo, Y., Zhang, X., Sirkar, K. K., & Xu, X. (2026) · ACS Nano · doi:10.1021/acsnano.6c00729
Design and development of lipid nanoparticle formulations for brain gene therapy
Thomson, S. B., Gomes, A. D. M., Kazemian, P., Kurek, D. Z., Kulkarni, J. A., Saadati, F., Wagner, P. K., Petkau, T. L., Ciufolini, M. A., Cullis, P. R., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103025
Ri, Y., Oshima, S., Tanaka, H., Sugawara, T., Hori, M., Siril, Y. J., Nakai, Y., Ito, K., Shimoya, K., Sakurai, Y., et al. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c00925
Degey, M., Pedergnana, S., Évrard, B., Piel, G., Debuigne, A., & Berger, M. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2699381
From nanoscale to clinic: The growing impact of nanotechnology in translational drug delivery
Vargas, R., Martos-Kikut, F., Martínez-Martínez, N., Lara-Guerrero, E., Lizano-Barrantes, C., Molina, J. A. P., Romero-Obón, M., Rouaz-El-Hajoui, K., García‐Montoya, E., Pérez‐Lozano, P., et al. (2026) · ADMET & DMPK · doi:10.5599/admet.3495
“However, they are neutral at physiological pH, which helps minimize toxic effects during systemic circulation [124,125,129].”
Advances and Challenges in Nanodelivery Systems for RNA Vaccines
Li, H., Zhao, Y., Yang, J., Guo, J., Cai, H., & Tong, A. (2026) · ACS Nano · doi:10.1021/acsnano.6c10327 · Cited by 2
Zhang, W., Hui, C., & Tan, M. (2025) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/ors55s2voz
Silva, M. C. C. D., & Pereira, J. (2025) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/l143898370
Nanomedicine Manufacturing Systems: Scale-Up Fragility, Reproducibility, and Quality Translation
Martins, B., Pereira, L., Azevedo, R., & Costa, P. (2025) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/a764521438
Larsson, S., Johansson, E., & Nilsson, A. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/n105134582
Step-by-Step Assembly Simulation of Lipid Nanoparticles with Encapsulated Nucleic Acid
Shmykov, B., Zaborova, O. V., Timoshenko, V. A., & Sergeyev, V. G. (2026) · Moscow University Chemistry Bulletin · doi:10.3103/s0027131426700252
Zhen, Z., Darji, M., Shih, K., Lin, X., Prajapati, R., Ranjbar, S., Dan, N., Shenouda, G., Hu, J., Bogner, R., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115412
Park, D., Lee, B., Ma, J.-H., Kim, Y., Hwang, J. S., Lee, H. W., Yoo, M. H., Kim, U.-K., & Kwon, T.-J. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100675
“…associated with LNPs include particle size, PDI, and EE; particle size significantly impacts mRNA encapsulation efficiency and half-life, which is crucial in enhancing cellular uptake, with smaller particles generally yielding higher delivery efficiency (Tenchov et al., 2021; Evers et al., 2018).”
InfluentialJeong, H., Park, C. H., Kim, B., Doh, J., & 구희범 (2026) · Lab on a Chip · doi:10.1039/d6lc00477f
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
Ionizable Lipid Nanoparticles as a siRNA Delivery Carrier: A Review
Prajapat, V., Sharma, G., Dhania, N. K., & Maparu, A. K. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.6c03278
Joseph, A. T., & Ravindran, S. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2752934
Metadata
- Authors
- Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M.
- Affiliations
- University Medical Center Utrecht (NL)
- University of British Columbia (CA)
- Department of Clinical Chemistry and Haematology University Medical Center Utrecht Heidelberglaan 100 3584 CX Utrecht The Netherlands
- Corresponding author
- Schiffelers, Raymond M.
- Venue
- Small Methods
- Publisher
- Wiley
- Published
- 2018-04-26
- Volume
- 2
- Issue
- 9
- ISSN
- 2366-9608 (ISSN-L)
- OpenAlex
- W2799813152
- Cited by
- 332
- References
- 153
- Citations by year
- 2026: 52 · 2025: 55 · 2024: 56 · 2023: 58 · 2022: 52 · 2021: 32 · 2020: 15 · 2019: 9 · 2018: 2
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- Locations
- Small Methods (publishedVersion, public-domain)
- TU/e Research Portal (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- H2020 LEIT Nanotechnologies (721058, # 14385, # 13667)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Canadian Institutes of Health Research (148469)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid nanoparticles, siRNA delivery, non-viral gene delivery, pharmacokinetics, gene silencing, mRNA delivery, CRISPR/Cas9 delivery, scalable fabrication, experimental design, nucleic acid carriers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
